The Positive Correlations between the Expression of Histopathological Ubiquitin-Conjugating Enzyme 2O Staining and Prostate Cancer Advancement.
UBE2O
prostate cancer
ubiquitin
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
08 Aug 2021
08 Aug 2021
Historique:
received:
26
05
2021
revised:
19
07
2021
accepted:
06
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
The mTOR signaling pathway is inactivated by AMPK's tumor-suppressing function. It is recognized that ubiquitin conjugating enzyme 2O (UBE2O), which directly targets AMPK for ubiquitination and degradation, is intensified in human cancers. This study investigated the clinical data about prostate cancer. Examination was also carried out into tissue microarrays (TMA) of human prostate cancer ( Very strong positive correlations were identified between the expression of UBE2O staining and high PSA and pathological stage of prostate cancer. Cox's proportional hazard analysis established correlations between the following: (1) positive surgical margin and biochemical recurrence free survival, (2) PSA grade and clinical recurrence free survival, (3) regional lymph node positive and clinical recurrence free survival, (4) adjuvant treatment and overall survival, and (5) pathological T stage and overall survival. There is a positive correlation between the expression of UBE2O staining and prognosis for prostate cancer. Thus, a prostate cancer prognosis can be assessed with the expression of UBE2O staining.
Sections du résumé
BACKGROUND
BACKGROUND
The mTOR signaling pathway is inactivated by AMPK's tumor-suppressing function. It is recognized that ubiquitin conjugating enzyme 2O (UBE2O), which directly targets AMPK for ubiquitination and degradation, is intensified in human cancers.
METHODS
METHODS
This study investigated the clinical data about prostate cancer. Examination was also carried out into tissue microarrays (TMA) of human prostate cancer (
RESULTS
RESULTS
Very strong positive correlations were identified between the expression of UBE2O staining and high PSA and pathological stage of prostate cancer. Cox's proportional hazard analysis established correlations between the following: (1) positive surgical margin and biochemical recurrence free survival, (2) PSA grade and clinical recurrence free survival, (3) regional lymph node positive and clinical recurrence free survival, (4) adjuvant treatment and overall survival, and (5) pathological T stage and overall survival.
CONCLUSION
CONCLUSIONS
There is a positive correlation between the expression of UBE2O staining and prognosis for prostate cancer. Thus, a prostate cancer prognosis can be assessed with the expression of UBE2O staining.
Identifiants
pubmed: 34451875
pii: ph14080778
doi: 10.3390/ph14080778
pmc: PMC8398491
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Foundation of Korea
ID : 2018R1A2B6001693
Références
Cell Metab. 2013 Jan 8;17(1):113-24
pubmed: 23274086
Mol Cell Biochem. 2014 Jan;386(1-2):63-71
pubmed: 24096736
Oncogene. 2006 Mar 2;25(9):1424-33
pubmed: 16247453
FEBS J. 2019 Jun;286(11):2018-2034
pubmed: 30468556
Am J Pathol. 2011 Mar;178(3):997-1008
pubmed: 21356353
Cancer. 2005 Jul 15;104(2):290-8
pubmed: 15948174
Blood Cancer J. 2011 Nov;1(11):e40
pubmed: 22829077
Nat Rev Mol Cell Biol. 2009 Nov;10(11):755-64
pubmed: 19851334
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
BMC Cancer. 2009 Sep 01;9:307
pubmed: 19723334
PLoS One. 2015 Dec 17;10(12):e0144708
pubmed: 26678268
Breast Cancer Res. 2014 Nov 22;16(6):466
pubmed: 25416589
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Mol Cell. 2008 Apr 25;30(2):214-26
pubmed: 18439900
BMC Biol. 2013 Apr 15;11:36
pubmed: 23587167
CA Cancer J Clin. 2017 May 6;67(3):245-253
pubmed: 28222223
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2554-9
pubmed: 24550282
Semin Cell Dev Biol. 2011 Aug;22(6):544-50
pubmed: 21477659
Cancer Cell. 2017 Feb 13;31(2):208-224
pubmed: 28162974
Hum Genomics. 2015 Sep 15;9:22
pubmed: 26374103